CN49 A rapid review of patient reported outcomes for patients with renal cell cancer or hepatocellular cancer on treatment with targeted therapies

Díez de los Ríos de la Serna, C., Kotronoulas, G., Drury, A., Oldenmenger, W.H. and Kelly, D. ORCID: https://orcid.org/0000-0002-1847-0655 2021. CN49 A rapid review of patient reported outcomes for patients with renal cell cancer or hepatocellular cancer on treatment with targeted therapies. Annals of Oncology 32 (S5) , S1274. 10.1016/j.annonc.2021.08.679

Full text not available from this repository.

Abstract

Targeted therapies are an efficacious treatment option for patients with advanced renal cell carcinoma (RCC) or hepatocellular carcinoma (HCC). Targeted therapies often have low-grade toxicities that may not require intervention but may be persistent and difficult to live with, thus affecting patients’ quality of life and adherence to treatment. Patient-reported outcomes (PROs) are key indicators of health status and functioning, coming directly from the patient. Comprehensive monitoring of PROs enables implementation of person-centred care. Currently, what PROs patients with RCC or HCC consider of utmost importance remains unknown. As part of the EONS PROMs project, a rapid literature review was carried out to identify PROs commonly assessed/reported in clinical studies of patients with advanced RCC/HCC on targeted therapies. A systematic search strategy was developed in line with PRISMA statement guidelines. We searched MEDLINE, CINAHL & PsycInfo for relevant peer-reviewed publications in the period from 2000-2021. Pre-specified selection criteria were applied to all retrieved records. Findings were integrated into a narrative synthesis. From a total of 1377 records, 81 studies met our selection criteria and were retained. Most research was on advanced RCC (n=64, 79%). 46 studies (57%) were drug trials. No qualitative research on PROs was found. Twenty-six studies (32%) employed PROs as their primary endpoint. PROs mainly featured as secondary endpoints, particularly where treatment efficacy (survival) was the focus of the study. Across studies, assessed PROs were similar for both RCC and HCC, and concerned three main areas: health-related quality of life, symptoms (cancer-related and treatment-related), and functioning. Whether selection of these PROs was patient-driven was not reported. A wide range of assessed PROs were reported, however which PROs matter the most to patients with advanced RCC/HCC must be further clarified. Deficits in PROs often cause patients to seek out help. Targeting, monitoring, and responding to the ‘right’ PROs can enhance provision of person-centred care in advanced RCC/HCC and augment the clinical efficacy of targeted therapies.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Healthcare Sciences
Publisher:	Elsevier
ISSN:	0923-7534
Last Modified:	10 Nov 2022 10:00
URI:	https://orca.cardiff.ac.uk/id/eprint/145350

Actions (repository staff only)

Edit Item